Contrast safety in the cancer patient: preventing contrast-induced nephropathy.
Contrast safety in the cancer patient: preventing contrast-induced nephropathy.
复制标题
DOI：
10.1102/1470-7330.2008.9018
复制
发表时间：
2008-10-04
期刊：
影响因子：
--
通讯作者：
Heiken JP
中科院分区：
文献类型：
--
作者：
Heiken JP
癌症患者经常接受影像学检查。用于肿瘤分期和评估治疗反应的计算机断层扫描（CT）检查通常需要给予血管内造影剂。用于CT的碘化造影剂与造影剂诱导的肾毒性（CIN）风险相关，特别是在肾功能受损和糖尿病患者中。在许多癌症患者中，血管内造影剂给药的并发症风险因高龄、脱水和同时给予肾毒性化疗药物而加剧。在这篇文章中，我回顾了CIN的定义，临床表现，可能的机制和危险因素，并提供预防这种潜在的危及生命的并发症的建议。
Cancer patients undergo frequent imaging examinations. Computed tomography (CT) examinations for tumor staging and assessment of treatment response generally require administration of intravascular contrast medium. Iodinated contrast agents for CT are associated with the risk of contrast-induced nephrotoxicity (CIN), particularly in patients with impaired renal function and diabetes. In many cancer patients the risk of complications from intravascular contrast medium administration is compounded by advanced age, dehydration and coadministration of nephrotoxic chemotherapeutic drugs. In this article I review the definition, clinical manifestations, possible mechanisms and risk factors for CIN, and provide recommendations for prevention of this potentially life-threatening complication.